GSK plc (GSK)
| Market Cap | 75.53B |
| Revenue (ttm) | 35.73B |
| Net Income (ttm) | 7.93B |
| Shares Out | 2.04B |
| EPS (ttm) | 4.09 |
| PE Ratio | 9.83 |
| Forward PE | 9.23 |
| Dividend | $1.36 (3.67%) |
| Ex-Dividend Date | Nov 16, 2023 |
| Volume | 1,488,199 |
| Open | 36.95 |
| Previous Close | 37.09 |
| Day's Range | 36.95 - 37.18 |
| 52-Week Range | 33.20 - 38.32 |
| Beta | 0.27 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2024 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc a... [Read more]
Financial Performance
In 2022, GSK plc's revenue was 29.32 billion, an increase of 18.74% compared to the previous year's 24.70 billion. Earnings were 14.96 billion, an increase of 241.07%.
Financial numbers in GBP Financial StatementsNews
GSK to cut US prices for Advair, Valtrex and Lamictal
Drugmaker GSK Plc said on Friday that it will cut U.S. list prices on asthma drug Advair, herpes drug Valtrex, and anti-epileptic medication Lamictal on Jan. 1, 2024.
GSK, Amneal, Kaléo delist patents from FDA's orange book
Pharmaceutical companies, GSK (GSK), Amneal Pharmaceuticals (AMRX) and Kaléo have agreed to delist some of their patents from the FDA's orange book. GSK withdrew four inhaler patents and Amneal withdr...
GSK agrees to pay up to $1.7 billion for antibody-drug conjugate
GSK PLC GSK, +0.11% said Wednesday that it has agreed to pay $185 million up front and up to $1.525 billion in success-based milestone payments to license an antibody-drug conjugate from Chinese bioph...
GSK's cancer drug combination meets primary goal in late-stage trial
GSK said on Monday that a combination of its cancer drugs Zejula and Jemperli, when as used as a maintenance therapy following Jemperli plus chemotherapy, met the main goal of a late-stage trial to tr...
EU watchdog deals blow to GSK blood cancer drug Blenrep
Europe's health regulator stuck to its recommendation not to renew conditional approval for GSK's blood cancer drug Blenrep on Friday, citing data that did not confirm its effectiveness.
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
PHILADELPHIA--(BUSINESS WIRE)--GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity.
These biotechs targeting multiple neurodegenerative diseases
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive...
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
GSK CEO Emma Walmsley said on Thursday that the British drugmaker's respiratory syncytial virus (RSV) vaccine Arexvy would generate more than 1 billion pounds ($1.26 billion) in its first year on the ...
GSK says blood cancer drug meets primary goal in late-stage trial
British drugmaker GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment, had met its primary goal of progression free survival in a late-stage trial.
Cameroon receives first shipment of GSK's Mosquirix malaria vaccine
Cameroon received its first shipment of Mosquirix malaria vaccines manufactured by British drugmaker GSK Plc late on Tuesday, as the nation struggles with the mosquito-borne disease that kills more th...
EU regulator backs GSK's bone marrow cancer therapy
British drugmaker GSK on Monday said the human medicines committee of the European Medicines Agency had recommended approving its oral therapy to treat anaemia in patients with a type of bone marrow c...
GSK's India unit posts Q2 profit rise on strong vaccine demand
GlaxoSmithKline Pharmaceuticals reported a 12.5% rise in quarterly profit on Thursday as the Indian unit of UK's GSK plc saw strong demand for its vaccines and general medicine.
GSK is a remedy for the winter investment blahs
GSK NYSE: GSK is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to go bef...
GSK beats on top and bottom lines after strong launch of RSV vaccine
CNBC's Angelica Peebles joins 'Squawk Box' to break down the company's quarterly earnings results.
GSK Boosts Profit Forecasts After ‘Outstanding' RSV Vaccine Launch
High demand for the vaccine pulled in around $850 million during the third quarter—reportedly double what analysts were expecting—and GSK said annual sales could top $1 billion.
GSK raises annual forecasts again on strong Arexvy launch
GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its ...
GSK Reports Earnings Wednesday. What to Watch.
The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.
GSK signs $1 bln deal for exclusive license to J&J's hepatitis B therapy
British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepat...
Pfizer RSV vaccine lags GSK's as head-to-head competition underway
Pfizer , which dominated COVID vaccine sales, now finds itself looking up at GSK , whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this s...
GSK says endometrial cancer drug meets primary goal in late-stage trial
British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.
RSV vaccine from GSK shows potential to protect adults 50 to 59
The results suggest that GSK's shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.
New Data for AREXVY, GSK's RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--New data for AREXVY, GSK's RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease.
RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says
GSK said they plan to submit data to regulators as soon as possible and expect a decision in 2024 on whether the shot, already approved for older adults, can be marketed towards people ages 50 to 59.
GSK's RSV vaccine shows positive results in adults aged 50-59
British drugmaker GSK said on Wednesday its vaccine for respiratory syncytial virus (RSV) showed potential in a late-stage trial to help protect adults aged 50 to 59 years.
GSK Settles Zantac Cases After Claims Popular Heartburn Drug Causes Cancer
The pharma giant settled four cases in California for an undisclosed amount to avoid the “distraction” of a trial.